Mixed results FOR CLL treatments availble through the CDF as the final verdict following the latest round of the CDF prioritisation review is made available. cllsupport.org.uk/news/posi...
NHS England have published today the new version 6 of the Cancer Drugs Fund list. Effective from today.
This new version supersedes earlier versions and follows on from all formal appeals and discussions between NCDF and drug companies following the September delisting announcements . This is now available. on the NHS England website: england.nhs.uk/ourwork/pe/cdf/ PDF of Version 6 Cancer Drugs Fund list england.nhs.uk/wp-content/u...
The good News: Ibrutinib has been retained on the CDF list with a small adjustment to inclusion criteria. This reverses the earlier September decision to remove it with one small exception.
This means that new CDF applications to access ibrutinib for treatment of relapsed/refractory CLL will now continue virtually as it was before the July re- prioritization review, NICE are also appraising Ibrutinb for long term availability through NHS England & Wales.
The Bad news: Bendamustine has been removed from the CDF list for treating relapsed CLL.
Read about the Blood Cancers Alliance response to Cancer Drugs Fund delistings - Letter published in the Times today healthunlocked.com/cllsuppo...
Tricia will be updating soon on our campaign and letters to MPs and the need for us to keep up pressure and continue with pressing for access .
Nick
Written by
HAIRBEAR_UK
Founder Admin
To view profiles and participate in discussions please or .
Lymphoma treatments readmitted to Cancer Drugs Fund - Lymphoma Association summary news article of the outcome of the latest CDF review in which CLL treatments are a major part: lymphomas.org.uk/about-us/n...
I would like to believe that all of our efforts together with the wider CLL community, the voice of other charities and stakeholders had some influence in the positive outcomes. Ultimately the drug companies had to continue discussion and negotiations with the NCDF and NHS. How much they were influenced we may never know!
We should continue to press for improvement as access to some treatment options have still been reduced/made more difficult by the CDF prioritization process. The whole appraisel and access process is set to change and the patient community must play a future role in ensuring effective blood cancer drugs come available to NHS patients and their clinicians– This we are pressing for in partnership with all UK blood charities and the clinical community cllsupport.org.uk/news/bloo...
Thank you Tricia and the CLLSA team for coordinating with the clinical community, other charities and stakeholders and the great many of you who wrote to your MPs and are prepared to continue to provide your voice and influence as needed..
We still have a long way to go but together we as a patient group can work to ensure we are appropriately engaged and listened to as stakeholders in the run up to and during the consultation planned as the NICE/CDF system evolves.
'Janssen is extremely pleased that NHS England has confirmed that Janssen-Cilag International NV's (Janssen) ibrutinib (IMBRUVICA®) will remain on the Cancer Drugs Fund (CDF) for the treatment of two types of blood cancer, Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL). This means that this important treatment option will continue to be available to eligible relapsed/ refractory CLL and MCL patients in England. This follows publication of the original list on 4 September which had identified ibrutinib for potential de-listing."
Leukaemia Care today published a good summary of the final outcome of the CDF prioritasion review across all blood cancers: What was removed from the CDf list on November 4th and What was planned for desisting but was retained. leukaemiacare.org.uk/news/c...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Ibrutinib denied to new patients
Cancer Drugs funding cuts in England. Can you please sit my online petition to David Cameron.
When to expect covid negative result after Paxlovid treatment
Canadian Study...treatment increases risk of secondary cancers in CLL
NHS decision takes away Ibrutinib from patients
